AVCTF.US Avacta Group Plc

Healthcare Biotechnology USA Stocks
0.7700 USD
Close of Nov 14, 2026
0.7384 1.23
Market cap
USD 337M
P/E
-
P/B
66.99x
ROE
-2,044.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is AVCTF.US undervalued?

Graham number

The Graham number of Avacta Group Plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Avacta Group Plc fundamental analysis

No fundamental analysis for Avacta Group Plc yet.

Avacta Group Plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Avacta Group Plc

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the ex…

Full company profile